NCT02245243View on ClinicalTrials.gov

Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Hepatic Impairment
Interventions
DRUG

Delafloxacin

Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz

Trial Locations (2)

32809

Melinta 112 Study Site, Orlando

33136

Melinta 112 Study Site, Miami

Sponsors
All Listed Sponsors
lead

Melinta Therapeutics, Inc.

INDUSTRY